Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research ConferenceSAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment ...

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has th ...

WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on Thursday, ...

At just 26 years old, Leah Adams heard the words no one wants to hear: malignant melanoma. In this powerful and emotional story, Leah shares how a routine skin check —prompted by her mother's intuition—led to a life-altering diagnosis. As a runner and only child, Leah's journey through surgery, recovery, and her father's parallel battle with stage 4 metastatic melanoma sheds light on how deeply this disease can impact families. Watch as Leah explains how the DecisionDx® Melanoma test helped guide her next s ...

fuboTV (FUBO) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Ameet Padte - SVP of FP&A, Corporate Development & Investor RelationsDavid Gandler - Co-Founder, CEO & DirectorJohn Janedis - CFOClark Lampen - Managing DirectorAlicia Reese - SVP - Equity Research Conference Call Participants David Joyce - Senior Equity Analyst - Media SectorLaura Martin - Managing Director, Senior Internet & Media Analyst Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your c ...

Air Products and Chemicals (APD) Q2 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 EBITDA, the effective tax rate and ROCE either on a total company or segment basis. Unless we specifically state otherwise, statements regarding these measures refer to our adjusted non GAAP financial measures. Reconciliations of these measures to our most directly comparable GAAP financial measures can be found on our investor website in the relevant earnings release section. Now I'll turn the call over to Eduardo. Spe ...

Perfect Corp (PERF) Q1 2025 Earnings Call April 28, 2025 08:00 PM ET Company Participants ​Jamie Shah - Director - Investor RelationsAlice H. Chang - Founder, Chairwoman of the Board & CEOPin-Jen Chen - Executive VP & Chief Strategy Officer Conference Call Participants Lisa Thompson - Senior AnalystPatrick McCann - Equity Research AnalystAashi Shah - Equity Research Analyst Operator Good morning, and good evening, ladies and gentlemen. Thank you for standing by, and welcome to the Perfect Corp. First Quarte ...

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. T ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The report highlights that China achieved a growth target of "around 5%" in 2024, with 70% of this growth driven by exports and export-related manufacturing investment [7]. - For 2025, the report anticipates a decline in real GDP growth to 4.0%, influenced by elevated US tariffs on Chinese goods, which are expected to impose a 2.2 percentage point drag on GDP growth [10][20]. - The report expresses caution regarding medium- to long-term GDP growth in China due to challenges related to demographics, debt, and de-risking, although there are moderate upside risks from faster AI adoption [9]. Summary by Sections Economic Forecasts - The report provides a detailed forecast for China's GDP growth, projecting 5.0% for 2024 and 4.0% for 2025, with a further decline to 3.5% in 2026 [15]. - It notes that domestic demand is expected to contribute positively, with consumption growth projected at 5.3% in 2025 [11]. Tariff Impact - The report indicates that the effective US tariff rate on China has reached 107%, significantly affecting trade dynamics and economic growth [20]. - It emphasizes that the ongoing policy easing in China may not fully offset the negative impacts of these tariffs [12]. Policy Measures - The report outlines expected policy measures, including further monetary easing and fiscal stimulus, to support economic growth amid external pressures [31]. - It anticipates an increase in the augmented fiscal deficit to 14.5% of GDP in 2025, up from 10.4% in 2024 [33]. Sectoral Insights - The report discusses the property sector, noting that construction activity has sharply contracted compared to previous peaks, raising questions about the sustainability of any recovery [52][56]. - It also highlights that high-tech manufacturing has been a stable growth driver over the past decade, with expectations that these sectors will continue to outperform broader manufacturing [80][84].

CytomX Therapeutics (CTMX) Q4 2024 Earnings Call March 06, 2025 05:00 PM ET Company Participants Chris Ogden - Chief Financial OfficerSean A. McCarthy - Chairman & CEOPriyanka Grover - Vice President - Biotechnology Equity ResearchDaniel Smith - Equity Research Associate Conference Call Participants Roger Song - Senior Equity Research AnalystJoseph Catanzaro - Director & Senior Equity AnalystPeter Lawson - Analyst Operator Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeuti ...